Power partnership oncology at MD Anderson expands access to expert cancer care, research, and clinical trials across seven U.S. health systems.

Ochsner Health announced on Thursday it has entered a 10-year partnership with The University of Texas MD Anderson Cancer Center to provide local patients access to the same treatments and trials ...

Pulse Biosciences has entered a research partnership with The University of Texas MD Anderson Cancer Center, US, to ...

MD Anderson Cancer Center has implemented a hiring pause for some positions and cut back "non-essential" spending after seeing a budget shortfall through the first half of the fiscal year, according ...

Ochsner Health is expanding its partnership with The University of Texas MD Anderson Cancer Center to Slidell Memorial Hospital, bringing one of the nation’s most advanced cancer treatment programs to ...

HOUSTON — MD Anderson Cancer Center received its first shipment Monday of the Pfizer coronavirus vaccine, launching a major effort to vaccinate frontline healthcare workers in the Texas Medical Center ...

Two of the Houston area's largest hospitals — The University of Texas MD Anderson Cancer Center and Texas Children's Hospital — have announced they will soon be entering a joint venture to combat ...

The University of Texas MD Anderson Cancer Center in Houston saw a significant drop in adjusted income in the seven-month period that ended March 31, which it blames on a costly Epic EHR ...

The Brief keeps Texas voters and political observers up to speed on the most essential coverage of their elected officials, the policies that shape their daily lives and the future of our great state.

These results establish proton therapy as a transforming, safe, and patient-focused solution, poised to redefine the global standard of care for oropharyngeal cancer.

MD Anderson Cancer Center, Houston's second-largest employer, is eliminating about 1,000 jobs as the elite medical institution continues to wrestle with losses that exceeded $100 million last quarter.

Collaboration supports co-development of RB-340, a HER-2 targeted CAR T- cell therapy with context-dependent and inducible down-regulation of PD-1, through Phase 2 HOUSTON & MENLO PARK, ...